Page 18 - காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால Today - Breaking & Trending Today

BioNTech SE: Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

(1)
Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose
Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration
Vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent
Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose ....

South Africa , New York , United States , United Kingdom , Sylke Maas , Albert Bourla , Chuck Triano , Ugur Sahin , Fosun Pharma , Jerica Pitts , Centers For Disease , Us Centers For Disease , Pfizer Inc Nasdaq , Drug Administration , Bayer Animal Health , Exchange Commission , European Union , Roche Group , Vaccine Administration Under Emergency Use Authorization , Disease Control , Biologics License Application , Chief Executive Officer , Marketing Authorizations Holder , Emergency Use Authorization , Adverse Events , Fact Sheet ,

Investegate |BioNTech SE Announcements | BioNTech SE: Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

BioNTech SE (Nasdaq: BNTX) today announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing that the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA). Safety data from the Phase 3 study has also been collected from more than 12,000 vaccinated participants who had a follow-up time of at least six months after the second dose, demonstrating a favorable safety and tolerability profile. ....

South Africa , New York , United States , United Kingdom , Sylke Maas , Albert Bourla , Chuck Triano , Ugur Sahin , Fosun Pharma , Jerica Pitts , Centers For Disease , Us Centers For Disease , Drug Administration , Bayer Animal Health , Exchange Commission , Pfizer Inc , European Union , Roche Group , Vaccine Administration Under Emergency Use Authorization , Confirm High Efficacy , Six Months Following Second Dose , Updated Topline Analysis , Disease Control , Biologics License Application , Chief Executive Officer , Emergency Use Authorization ,

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

United States , Kevin Hern , Bryan Dunn , Steve Danehy , Steven Taylor , Ken Verburg , Eli Lilly , Arthritis Advisory Committee , Drug Administration , Advisory Committee , Pfizer Global Product Development , Lilly Alliance , Exchange Commission , Pfizer Inc , Risk Management Advisory Committee , Arthritis Foundation , Joint Arthritis Advisory Committee , Drug Safety , Pfizer Global Product , Biologics License Application , Pfizer Lilly Alliance , Breakthroughs That Change Patient Lives , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future ,

Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Albert Liao , Bryan Crowe , Steve Danehy , James Rusnak , Chuck Triano , Arjona Ferreira , Ayman Al Hendy , Juan Camilo Arjona Ferreira , Program Steering Committee Member , Program In Uterine Fibroids , Global Product Development At Pfizer , Pfizer Inc , University Of Chicago , Myovant Sciences Forward , Drug Administration , Myovant Sciences , Myovant Sciences Conference Call , Exchange Commission , Myovant Sciences Contacts , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Wall Street , Steering Committee , Chief Medical Officer ,

Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Albert Liao , Steve Danehy , James Rusnak , Chuck Triano , Arjona Ferreira , Juan Camilo Arjona Ferreira , Ayman Al Hendy , Program Steering Committee Member , Program In Uterine Fibroids , Global Product Development At Pfizer , Pfizer Inc , University Of Chicago , Myovant Sciences Forward , Drug Administration , Myovant Sciences , Myovant Sciences Conference Callmyovant , Exchange Commission , Myovant Sciences Contactsryan Crowe , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Steering Committee , Chief Medical Officer , Senior Vice President , Chief Development Officer ,